The third-party payment system represents a major advancement in the French healthcare system, facilitating access to care by eliminating upfront costs for insured individuals. However, faced with the ongoing rise in the costs of expensive treatments, the Health Insurance has decided to strengthen the conditions surrounding this mechanism. This approach aims to reconcile cost control of public spending with the preservation of the right to health, a crucial issue for both insured persons and healthcare professionals. In 2025, this regulatory adjustment takes place in a context marked by rising therapeutic prices and increased expenses related to new medical technologies, including costly innovative treatments.
The stated goal is to reduce the risks of uncontrolled overspending while ensuring a more targeted and responsible coverage of high-impact medical acts. The new standards imposed modify the application procedures of the third-party payment system among relevant medical actors, particularly for expensive medications and specialized therapies, provoking debate among healthcare professionals, insurance companies such as Macif, Groupama, MAIF, or Allianz, as well as patient representatives.
As digitalization and dematerialization of reimbursement processes progress, innovative tools such as Viamedis TP or Oxantis now offer advanced technical solutions for optimized management of third-party payments. This dynamic contributes to better financial security for professionals and represents a significant evolution in the relationship between insured persons and their insurers, including Axa, Generali, LCL Assurance, or Swiss Life. This tightening of conditions finally raises several fundamental questions about equitable access to care and the quality of coverage, at the heart of current debates on social protection reform.
New regulation of third-party payment for costly treatments: legal framework and issues
The strengthening of third-party payment conditions mandated by Health Insurance is part of a precise legal framework designed to regulate coverage of costly acts. The regulation primarily relies on decree nยฐ 2016-1069 of August 3, 2016, amended, which sets out guarantees and obligations to ensure proper application of the third-party payment system. Since 2024, additional measures have been adopted to specify how third-party payment is used for treatments of high therapeutic value, especially those listed as costly acts and services (APO) by the French National Authority for Health (HAS).
Furthermore, healthcare professionals now must present strengthened proof of eligibility for third-party payment for the acts concerned, an evolution aimed at reducing fraud but also better controlling costs. This requirement particularly impacts the private hospital sector and outpatient care structures. The Health Insurance highlights these new obligations in practical guidelines available on Ameli.fr.
The implementation of these standards results in:
- Strict control of immediate coverage rights, with verification of social security certificates
- An updated list of treatments considered costly and subject to specific conditions for third-party payment
- Increased accountability of healthcare professionals regarding billing and declaration of relevant acts
- Enhanced control actions jointly conducted by Health Insurance and partner supplementary organizations such as MAIF or MMA
It should be noted that these measures also aim to ensure greater transparency in the care pathway, helping to prevent financial overspending risks for insured persons and professionals. According to Juridique-Lab, this development raises questions about the proper balance between safeguarding the system and facilitating access to essential treatments.
The impact of stricter rules on insured persons and healthcare professionals
The tightening of rules governing third-party payment for expensive treatments directly impacts beneficiaries, whether they are patients, doctors, or pharmacists. Insured persons, especially those covered by organizations like Macif, Allianz, or Swiss Life, now need to ensure their rights are properly registered and that the specific conditions for applicable third-party payment are met.
For healthcare professionals, strict application of new obligations requires increased vigilance during consultations and billing. A hospital practitioner, for example, must verify the patientโs eligibility for third-party payment for a costly treatment, which may lead to longer administrative procedures and consequently a higher volume of controls. This increased rigor can paradoxically result in shorter processing times overall, thanks to the use of dedicated digital tools.
However, this tightening raises several issues:
- ๐ Risk of partial exclusion of some patients who are not fully familiar with the procedures or required criteria
- โ๏ธ Difficulties for professionals in managing administrative tasks, increasing non-medical workload
- ๐ก Need to include specific training on the new rules for practitioners
- ๐ Strengthening of data protection and control systems to combat possible fraud
Platforms such as Viamedis TP position themselves as facilitators in this context, automating the verification of rights and payment management. This technological advance is appreciated by insurance organizations like Groupama and LCL Assurance, committed to ensuring a system that is both secure and efficient. A report published in 2025 emphasizes that digitalization is a key lever for reducing errors and improving satisfaction among patients and professionals.
| Involved Actors ๐ฅ | Consequences of stricter rules ๐ | Proposed solutions ๐ก |
|---|---|---|
| Insured persons (patients) | Increased need for proof, risk of rejection of third-party payment | Enhanced information via Ameli websites, additional support |
| Healthcare professionals | Increased administrative procedures, greater responsibilities | Training, digital solutions (Viamedis TP, Oxantis) |
| Insurance organizations (MAIF, MMA) | Enhanced monitoring and management of non-compliance risks | Close collaboration with Health Insurance, regular audits |
Costly treatments affected by new third-party payment conditions
The scope of treatments subject to strengthened third-party payment conditions has been defined to target acts with high financial intensity, often characterized by a significant unit cost or usage frequency generating substantial expenses. This evolving list, regularly updated by the French National Authority for Health (HAS), notably includes:
- ๐ High-cost medications, such as some innovative anticancer drugs or treatments for rare diseases
- ๐ฉบ Specialized surgical procedures in private or public hospitals
- ๐งฌ Technological medical devices (insulin pumps, specific implants)
- ๐จโโ๏ธ Long-term treatments likely to mobilize considerable budgets
The precise definition of these acts can be accessed on the official portal sante.gouv.fr. For each treatment, maximum thresholds are set, beyond which coverage requires specific conditions, such as prior approval requests or reinforced justification within the medical record.
This regulation thus proposes a hierarchy of medical acts eligible for third-party payment, with:
- A “standard” category with generalized third-party payment for common acts
- An “intermediate” category subject to verifications and additional conditions
- A “demanding” category reserved for extremely costly acts with reinforced intervention from payers
This classification allows actors such as Axa, Generali, or Swiss Life to better calibrate their supplementary offers in connection with the coverage provided by Health Insurance. Optimizing care pathways and reducing the risks of overspending become essential levers to ensure system sustainability.
| Act categories ๐ท๏ธ | Examples โ๏ธ | Conditions for third-party payment ๐ก๏ธ |
|---|---|---|
| Standard | Routine consultations, generic medications | Automatic third-party payment |
| Intermediate | Costly imaging exams, specific treatments | Proofs required, reinforced control |
| Demanding | Innovative anticancer drugs, transplants | Prior approval, strict proof requirements |
It should be noted that actors like Viamedis TP contribute to simplifying the management of these treatments by automating administrative and financial controls, deemed necessary for proper implementation of third-party payment.
The role of insurance companies in reinforced third-party payment management
Insurance companies play a crucial role in framing and facilitating third-party payment, particularly in managing costly treatments. Major groups such as Macif, Groupama, MAIF, Allianz, MMA, Generali, LCL Assurance, or Swiss Life collaborate closely with Health Insurance to harmonize procedures and limit financial risks.
These supplementary insurers intervene at several levels:
- ๐ค Negotiation of specific coverage protocols with public organizations
- ๐ Analysis of financial flows and detection of anomalies in reimbursements
- ๐ฅ๏ธ Implementation of innovative digital platforms facilitating third-party payment management (e.g., systems offered by Oxantis)
- ๐ Training and informing insured persons about their rights and new regulations in effect
The good collaboration between Health Insurance and supplementary insurers intensifies, notably through secure data exchanges aimed at enhancing transparency and limiting abuses. The interest of these partnerships is also economic: they reduce costs related to overspending in costly acts while preserving care quality.
Furthermore, insurance companies adapt their offerings to incorporate these new modalities. For example:
| Insurance company ๐ฉ | Specific actions ๐ ๏ธ | Benefits for insured persons ๐ |
|---|---|---|
| Macif | Integrated digital platform for reinforced third-party payment | Facilitated access to reduced upfront costs |
| Groupama | Dedicated customer service for costly treatments | Personalized support |
| Axa | Modular solutions based on individual needs | Enhanced supplementary coverage |
| Swiss Life | Program informing insured persons about their rights | Increased knowledge of procedures |
Technological tools to optimize third-party management of costly treatments
Technological evolution is profoundly transforming third-party payment management, especially for costly treatments. Digital innovations enable better identification of insured personsโ rights, increased transaction security, and significant simplification of procedures for healthcare professionals. Solutions like Viamedis TP or Oxantis are notable advances.
These automated systems particularly allow:
- ๐ฑ Real-time verification of coverage and rights for third-party payment
- ๐ Secure and rapid transmission of administrative and medical files
- ๐ Protection of sensitive data in accordance with GDPR standards
- โ๏ธ Integration with billing systems to prevent deposit errors
For example, the Viamedis TP tool, referenced by many healthcare operators, offers an intuitive and configurable interface for pharmacies, clinics, and medical offices, thus facilitating compliance with the new rules. This digitalization aims to reduce billing errors and prevent possible suspicions of fraud.
The adoption of these tools is encouraged by companies like LCL Assurance, MMA, or Generali, who recognize the central role of new technologies in controlling healthcare expenses. Their gradual integration into the French medical landscape reflects a desire for modernization and increased efficiency.
| Technological feature ๐ง | Objectives ๐ฏ | Involved examples ๐ |
|---|---|---|
| Instant rights verification | Avoid unnecessary upfront payments | Viamedis TP, Oxantis |
| Secure data management | GDPR compliance, fraud prevention | Oxantis, insurance platforms |
| Automation of billing | Error reduction, time savings | Viamedis TP, LCL Assurance |
Perspectives on reforming third-party payment for costly treatments
The current strengthening of access conditions for third-party payment of costly treatments is part of an evolving process surrounding a broader healthcare reform in France. This renewed framework could eventually include:
- ๐ฅ An expansion of covered treatments according to technological advances in medicine
- ๐ More dynamic and accurately adjusted pricing to actual act costs
- ๐งโโ๏ธ Increased participation of healthcare professionals in defining eligibility criteria
- ๐ Better integration of supplementary health insurance into the reimbursement chain
This trajectory aims to strengthen expenditure control while maintaining universal access to care, a point closely monitored by institutions such as the French Health Insurance and associated mutual organizations. Simultaneously, greater focus will be placed on prevention mechanisms and support for patients with severe conditions.
A major challenge of this reform is balancing administrative rigor with flexibility in coverage, to avoid any disruptions in access to care. The announced developments continue to be closely followed by sector professionals and insurance organizations, which are gradually adapting their responses.
| Reform elements ๐ | Expected impact ๐ | Interested actors ๐ฅ |
|---|---|---|
| Expansion of covered treatments | Possible increase in costs, better therapeutic response | Insured persons, professionals, health insurance |
| Dynamic pricing | Precise adaptation, wastage reduction | Insurers, public funders |
| Participation of professionals | Improved patient follow-up | Doctors, pharmacists |
| Strengthening of supplementary coverage | Better financial coverage | Insurance companies |
Social issues related to tightening third-party payment for costly care
Beyond technical and economic aspects, tightening third-party payment rules primarily concerns the social dimensions of health. Access to costly treatments is a key marker of equality in healthcare, and any change to their coverage regime raises sensitive questions.
The risk highlighted is that of excluding the most vulnerable populations, notably those in precarious situations, seniors, or chronic patients, who may face additional difficulties in managing administrative files. It is therefore crucial that information and support systems remain strengthened.
- ๐ค Implementation of specific aid programs for fragile populations
- ๐ข Targeted awareness campaigns by organizations like French Health Insurance and some mutual organizations (e.g., MAIF, MMA)
- ๐งโโ๏ธ Reinforcement of the social role of healthcare professionals in guiding patients
- ๐ฅ Development of coordination between social and medical actors to facilitate care pathways
Actions are also undertaken to harmonize understanding of rules among involved actors, to reduce errors or unproductive rejections of third-party payment, which would be detrimental to social cohesion and public health. A comprehensive summary of these issues is available on service-public.fr.
Comparison of third-party payment approaches in Europe for costly treatments
The strengthening of third-party payment rules in France also offers an interesting perspective when compared to other European models. Several countries have adopted different strategies to regulate access to costly treatments while controlling public expenses.
For example :
- ๐ฉ๐ช In Germany, a mixed system combines universal coverage with reimbursement caps tailored to supplementary insurances
- ๐ฌ๐ง In the United Kingdom, the National Health Service remains the main funder, with strict administrative controls over expensive prescriptions
- ๐ธ๐ช In Sweden, centralized authorizations allow better expenditure planning, linking access to certain innovative therapies
- ๐ช๐ธ In Spain, decentralized management involves regional differences in third-party payment and reimbursement systems
This diversity highlights the common challenges faced by healthcare systems across Europe. France, with its new regulatory frameworks, seeks to strike a balance between economic efficiency and social equity amidst increasing pressure on health budgets.
| Country ๐ช๐บ | Approach to third-party payment for costly treatments ๐ฉบ | Key advantages โญ | Main limitations โ ๏ธ |
|---|---|---|---|
| France | Strengthening conditions, prior approval required | Increased control, prevention of abuse | Administrative complexity |
| Germany | Mixed system, strong supplementary insurance | Extended coverage | High private costs |
| United Kingdom | Centralized management by NHS | Uniformity and universal access | Waiting times, rationing |
| Sweden | Centralized authorization | Efficient planning | Rigidity, less flexibility |
| Spain | Decentralized regional management | Territorial adaptability | Regional inequalities |
Such comparative analysis underscores the importance of continuously adapting measures to each countryโs context, while taking social and economic challenges into account.
FAQ on reinforced third-party payment for costly treatments
- โ What is reinforced third-party payment for costly treatments?
This is a mechanism allowing insured persons not to pay upfront for expensive medical acts, subject to the compliance with stricter conditions imposed by Health Insurance. - โ What documents are necessary to benefit from third-party payment on costly treatments?
Patients must provide a validated rights certificate, and sometimes prior approval issued upon request by the healthcare professional. - โ How can healthcare professionals manage these new rules?
They need to follow specific training and rely on digital tools like Viamedis TP or Oxantis to verify rights and secure billing. - โ What impact does this tightening have on access to care?
It aims to optimize coverage while preventing abuses, but may complicate procedures, especially for vulnerable patients. - โ Where can I find reliable information on this subject?
Resources are available on Ameli and Assurances.fm.
Source: www.clicanoo.com
Entraรฎne-toi avec nos Quiz de rรฉvision
Fini les lectures passives. Pour retenir les notions clรฉs du BTS Assurance, teste-toi ! Inscris-toi pour recevoir 1 quiz par jour directement dans ta boรฎte mail.
